腹腔镜术中腹腔内热灌注化疗（HIPEC）治疗难治性恶性腹水：52例患者的多机构回顾性分析
Laparoscopic hyperthermic intraperitoneal peroperative chemotherapy (HIPEC) in the management of refractory malignant ascites: A multi-institutional retrospective analysis in 52 patients.
作者信息
Valle M, Van der Speeten K, Garofalo A
机构信息
Department of Surgical Oncology, Digestive Branch, Regina Elena National Cancer Institute, Rome, Italy.
出版信息
J Surg Oncol. 2009 Sep 15;100(4):331-4. doi: 10.1002/jso.21321.
Malignant ascites is a debilitating condition affecting cancer patients in their terminal stage of disease. Recently, laparoscopic hyperthermic intraperitoneal peroperative chemotherapy (HIPEC) was introduced as a new approach. From September 2001 to August 2008, 52 patients were treated with this new modality. No treatment-related mortality was observed. Median survival was 98 days. One patient developed a clinical recurrence. Laparoscopic HIPEC is a safe and effective method for palliating malignant ascites.
恶性腹水是一种使处于疾病终末期的癌症患者身体衰弱的病症。最近，腹腔镜术中热灌注化疗（HIPEC）作为一种新方法被引入。从2001年9月至2008年8月，52例患者接受了这种新治疗方式。未观察到与治疗相关的死亡病例。中位生存期为98天。1例患者出现临床复发。腹腔镜HIPEC是缓解恶性腹水的一种安全有效的方法。
Zotero 插件